Financial News

Financial Report: Baxalta

Revenues up 7% in the quarter

Baxalta

3Q Revenues: $1.6 billion (+7%)

3Q Earnings: $309 million (+26%)

YTD Revenues: $4.4 billion (+3%)

YTD Earnings: $861 million (-11%)

Comments: Hematology revenues were $935 million in the quarter, up 10% driven by heightened demand for ADVATE and FEIBA. Immunology sales were $626 million, up 13% with continued HYQVIA sales growth. BioTherapuetics sales were $191 million, up 7%. R&D expenses were $286 million, down 8%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters